AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7032642
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of seminal plasma antibodies
Trial: 12686336
Drug: Diet-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet-only treatment
Trial: 10226960
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication status before surgery
Trial: 29499287
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical injections)
Trial: 27465383
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula milk (IFM) containing 10.5 μg I/100 kcal
Trial: 27465383
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula milk (IFM) containing 19.3 μg I/100 kcal
Trial: 20720259
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg GLP-1
Trial: 20720259
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg PYY3-36
Trial: 18789007
Drug: Acridilol for
RxNorm normalized name: Acridinyl anisidide
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acridilol for 24 weeks with other antihypertensive therapy (n=291)
Trial: 18789007
Drug: Acridilol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acridilol therapy
Trial: 15991507
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% with 1:200000 epinephrine, 20 mL administered through a subphrenic catheter before incision closure and at 4-hourly intervals for the first postoperative 20 hours.
Trial: 15991507
Drug: Saline with
RxNorm normalized name: CVS Saline with Aloe Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline with 1:200000 epinephrine, 20 mL administered through a subphrenic catheter before incision closure and at 4-hourly intervals for the first postoperative 20 hours.
Trial: 12182251
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg/hydrochlorothiazide 25 mg (L100/25)
Trial: 12182251
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/12.5)
Trial: 10482058
Drug: Bordetella pertussis
RxNorm normalized name: Bordetella pertussis
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bordetella pertussis (single agent)
Trial: 10482058
Drug: Bordetella parapertussis
RxNorm normalized name: Bordetella parapertussis Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bordetella parapertussis (single agent)
Trial: 31709460
Drug: Dietary cobalt
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cobalt supplementation (up to 2 mg/kg)
Trial: 31709460
Drug: Dietary cobalt
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cobalt supplementation (3 mg/kg)
Trial: 31709460
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg Co dietary supplementation
Trial: 31455473
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg twice daily for 21 days followed by 20 mg once daily)
Trial: 31455473
Drug: Warfarin (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (heparin for 3 to 5 days followed by warfarin for 3 to 6 months)
Trial: 23589565
Drug: Xanthine oxidoreductase
RxNorm normalized name: xanthine
DrugBank: Xanthine (DB02134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthine oxidoreductase (XOR) inhibitor, allopurinol
Trial: 12643888
Drug: Bisoprolol low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol low dose (1.25, 2.5 or 3.75mg/day)
Trial: 12643888
Drug: Bisoprolol moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol moderate dose (5 or 7.5mg/day)
Trial: 12643888
Drug: Bisoprolol high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol high dose (10mg/day)
Trial: 2439786
Drug: Bisoprolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (all doses)
Trial: 12643888
Drug: Placebo low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo low dose
Trial: 12643888
Drug: Placebo moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo moderate dose
Trial: 12643888
Drug: Placebo high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo high dose
Trial: 10777470
Drug: Paclitaxel in
RxNorm normalized name: paclitaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel in combination with cisplatin or carboplatin
Trial: 1416572
Drug: Subcutaneous octreotide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide, 100 micrograms every 8 hours for 4 weeks
Trial: 1416572
Drug: 300 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms of octreotide daily for 6 months
Trial: 1416572
Drug: 750 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 micrograms of octreotide daily for 6 months
Trial: 4014015
Drug: Caffeine (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3.3 mg/kg body weight, equivalent to 2 to 3 cups of coffee)
Trial: 26027224
Drug: Usual intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual intensive therapy (IT)
Trial: 26027224
Drug: Differentiated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differentiated therapy for improvement of renal function
Trial: 1978680
Drug: Transdermal nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitrate
Trial: 10668944
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral trimethoprim-sulfamethoxazole
Trial: 1898998
Drug: Intravenous flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flecainide (2 mg/kg, maximum dose 150 mg) with digoxin (500 micrograms)
Trial: 7202238
Drug: Dexedrine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexedrine 2.5 mg twice daily
Trial: 7202238
Drug: Dexedrine 5
RxNorm normalized name: Dexedrine 5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexedrine 5 or 10 mg twice daily
Trial: 17079762
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment
Trial: 27030648
Drug: Blood purification
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood purification group (BP) received continuous venous‐venous hemodiafiltration in addition to conventional treatment.
Trial: 22236918
Drug: 3-monthly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly home visits for questionnaire-based TB screening plus record surveillance of TB registers, hospital admission and X-ray lists at health facilities for TB suspects and cases (Group 1)
Trial: 19415341
Drug: 750 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/day American ginseng
Trial: 19415341
Drug: 1,000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/day American ginseng
Trial: 27482750
Drug: 1.25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 g testosterone gel (Low T/E)
Trial: 27482750
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g testosterone gel with letrozole (Normal T/Low E)
Trial: 23235130
Drug: Daily chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chewing gum containing xylitol (A)
Trial: 12467070
Drug: Liposomal tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal tretinoin administered once weekly
Trial: 10840537
Drug: aprotinin (high-dose-scheme)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aprotinin (high-dose-scheme)
Trial: 10840537
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid (2 g/h)
Trial: 10840537
Drug: no antifibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no antifibrinolytic therapy (control group)
Trial: 6662766
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g fructose (F)
Trial: 29394188
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly low‐to‐moderate intensity resistance training
Trial: 26206077
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of fosaprepitant meglumine
Trial: 24990067
Drug: Saline infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infiltration (30 cc)
Trial: 20560029
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of CD133(+) bone marrow stem cells
Trial: 17654129
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (Seretide) 50/250 microg twice daily (SFC)
Trial: 17654129
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (Flixotide) 250 microg twice daily (FP)
Trial: 15857224
Drug: Single-wave bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-wave bolus (100% of insulin given immediately)
Trial: 15857224
Drug: 4-h dual-wave
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-h dual-wave bolus (50% of insulin given immediately and 50% given over a 4-h period)
Trial: 15857224
Drug: 8-h dual-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-h dual-wave bolus (50% of insulin given immediately and 50% given over a 8-h period)
Trial: 12145009
Drug: High-isoflavone diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone diet (56 mg isoflavones/d)
Trial: 12145009
Drug: Low-isoflavone diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone diet (2 mg isoflavones/d)
Trial: 31692016
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg, 4 times daily for 4 days)
Trial: 20593742
Drug: Oral galantamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral galantamine
Trial: 18287179
Drug: Pravastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin + vitamin E + homocysteine-lowering B-vitamin therapy
Trial: 17194264
Drug: Active TMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TMS treatment
Trial: 17194264
Drug: Active TMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TMS treatment with stimulation intensity below 90% of motor threshold
Trial: 11069333
Drug: Nasal first/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal first/oral second group
Trial: 11069333
Drug: Oral first/nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral first/nasal second group
Trial: 9118715
Drug: Inhaled and
RxNorm normalized name: Umeclidinium and Vilanterol Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled and systemic corticosteroids
Trial: 7917772
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of lazabemide (100‐300 mg)
Trial: 7917772
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of lazabemide (100‐350 mg 12 hourly for 7 days)
Trial: 7917772
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple dosing of lazabemide
Trial: 3288016
Drug: Pentoxifylline (slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (slow-release formulation) 3 x 400 mg/day for 8 weeks
Trial: 31379380
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), 30 weekly sessions
Trial: 29872288
Drug: GB 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB 12.5 μg BID
Trial: 29872288
Drug: GB 25
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB 25 μg BID
Trial: 29872288
Drug: GB 50
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB 50 μg BID
Trial: 25045258
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 μg
Trial: 28665378
Drug: General magnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General magnetic therapy in addition to initial therapy (medication, therapeutic physical exercises, aquatic therapy)
Trial: 28665378
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (initial therapy only)
Trial: 28665378
Drug: General magnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General magnetic therapy
Trial: 9847435
Drug: Levalbuterol 1.25
RxNorm normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol 1.25 mg
Trial: 15709454
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups (Levalbuterol and Racemic Albuterol)
Trial: 11470011
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist therapy
Trial: 11470011
Drug: Diuretic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic and beta-blocker therapy
Trial: 8635924
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding with a nasogastric tube
Trial: 8635924
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding without a nasogastric tube
Trial: 1617923
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg once daily)
Trial: 24760259
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation (5,000 IU daily)
Trial: 24047015
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal gel
Trial: 11239859
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine (5%) solution applied 10 and 5 minutes before surgery and vancomycin (20 microg/ml) in the irrigating fluid
Trial: 11239859
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo solution and irrigating fluid only without antibiotics
Trial: 9651405
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of elemental zinc daily for 6 months
Trial: 2198296
Drug: Zolpidem, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem, an imidazopyridine hypnotic compound
Trial: 23642977
Drug: Psycho-education along
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-education along with pharmacotherapy treatment
Trial: 21285531
Drug: MF59®-adjuvanted formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59®-adjuvanted formulation containing 7.5 μg antigen
Trial: 21285531
Drug: Non-adjuvanted formulations
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted formulations containing 15 or 30 μg antigen
Trial: 14760339
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of red wine
Trial: 14760339
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of dealcoholized red wine
Trial: 11740417
Drug: Unfractioned heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractioned heparin (UFH) - 5000 units s.c. x 3 daily
Trial: 8116325
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g every 6 hours for 24 hours
Trial: 8116325
Drug: Piritramide administration
RxNorm normalized name: piritramide
DrugBank: Piritramide (DB12492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piritramide administration in both groups
Trial: 3311480
Drug: Cortisone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone treatment (50 mg orally twice daily for 4 days)
Trial: 3311480
Drug: Control (absence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (absence of any medication)
Trial: 26537948
Drug: Septoplasty (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septoplasty (with or without concurrent turbinate surgery)
Trial: 10482088
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% topically twice daily for 29 days
Trial: 8735778
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of vitamin C for 14 days
Trial: 7038076
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of fresh-frozen plasma and platelets
Trial: 7038076
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no therapy directed specifically at the coagulopathy)
Trial: 24756025
Drug: BCI-Manus therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCI-Manus therapy
Trial: 17624196
Drug: Etoricoxib (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (90 mg, tablet)
Trial: 7645522
Drug: Diltiazem plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem plus trimetazidine (diltiazem 60 mg three times daily and trimetazidine 20 mg three times daily)
Trial: 2142741
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy (tissue plasminogen activator)
Trial: 2191485
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy (streptokinase)
Trial: 2142741
Drug: Combined trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined trials of intravenous thrombolysis
Trial: 23339726
Drug: Combination aliskiren/valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination aliskiren/valsartan 150/160 mg
Trial: 16804292
Drug: Ketoconazole 100
RxNorm normalized name: ketoconazole 100 % MISCELL CRYSTALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 100 mg/day
Trial: 27263310
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL normal saline
Trial: 27263310
Drug: 0 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mL normal saline (control group)
Trial: 18088197
Drug: Galantamine (16-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (16-24 mg/day)
Trial: 15519702
Drug: DTPa/Hib (PRP-T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa/Hib (PRP-T) booster dose
Trial: 15519702
Drug: Unconjugated PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconjugated PRP (PRP) challenge dose plus separate DTPa vaccine
Trial: 11356400
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy or other pharmacologic therapy started before discharge
Trial: 11356400
Drug: Systematic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic treatment plans for management of risk factors after hospitalization
Trial: 19265635
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with second-generation antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) combined with lithium or divalproex
Trial: 7617495
Drug: APF gel
RxNorm normalized name: APF Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF gel